Skip to content
MarketScale
‹ Back to IndustriesHealthcare

What Should Building Managers Do If COVID Doesn’t Go Away?

We all want the coronavirus to go away and for COVID-19, social distancing and everything that goes with it to be remembered as a horrible part of a weird year. There are some encouraging signs, with Pfizer announcing promising news about a vaccine candidate and other medical companies making progress. But what if the…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
What Should Building Managers Do If COVID Doesn’t Go Away?

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

We all want the coronavirus to go away and for COVID-19, social distancing and everything that goes with it to be remembered as a horrible part of a weird year.

There are some encouraging signs, with Pfizer announcing promising news about a vaccine candidate and other medical companies making progress. But what if the vaccine isn’t effective, the virus mutates or it returns in different forms, like the flu?

Those possibilities are why everyone, but especially building managers, must ask the question of what we do if COVID doesn’t go away, said John Shanahan, President of Ionogen.

“Maybe it’s a mutation or maybe the flu gets smarter. We have to have more long-term strategies for getting people back into business,” Shanahan said.

Shanahan has found his company’s hypochlorous solutions highly effective in Ionogen’s own office, with none of his team of 50 testing positive for COVID during the pandemic.

“In February, when this really started to ramp up, we deployed all the humidification devices in our building. Because we made surface sanitizers and disinfectants and they were still trying to figure out what COVID was, we put the air sanitizers up as a preventative measure,” he said. “We were so busy February, March, April and May that there was no stopping. But because we have both the physical staff in our manufacturing division and we needed to be able to collaborate, we just added more units into our space.”

Now, they’re looking into the positive results of hypochlorous actually getting into the upper respiratory areas and potentially killing the virus.

“We’re very excited about the future of where this is going to take us. We will continue, as always, to do more testing and trials and the continued research on this,” Shanahan said. “We’re committed to science, and we like proof. Anecdotes are great, and we’ve got a lot of anecdotes about how this has worked up until now. Now, we’ll continue to dig down into the science. Hypochlorous could very well be the antidote without having to take the immunization.”

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

The EU’s MDR delay buys time, but it won’t clear your commissioning bottleneck

The European Commission backed extending EU MDR transition deadlines to December 2027 and December 2028, Medical Design & Outsourcing reported. It buys time, not ramp-up capacity. Design News cites digital commissioning and machine digital twins to cut “power-on” surprises and speed validation and operator training.

  • 01If an EU portfolio includes Class III, December 2027 is now the planning anchor, but the internal gating item may shift to validation capacity and automation readiness, not paperwork.
  • 02Digital commissioning is becoming a procurement spec, not a buzzword, because it lets teams run DFM/DFA learning loops before hardware is built, which Design News notes is meant to reduce machine power-on surprises.

Sep 5, 2026

HCA’s Q1 was not about volume. It was about coverage and collecting cash

HCA Healthcare reaffirmed 2026 guidance after Q1 weather and a muted respiratory season cut adjusted EBITDA by about $180 million, according to HealthLeaders and Fierce Healthcare. Payer mix shifted fast. Exchange admissions fell about 15% and uninsured admissions rose about 16%, Fierce reported.

  • 01A mild flu season can be a margin event: HCA tied a 42% drop in respiratory admissions to a roughly $180M adjusted EBITDA hit (HealthLeaders, Fierce Healthcare).
  • 02The 2026 risk is sliding from demand to coverage: HCA cited a $600M–$900M full-year EBITDA headwind from exchange-related changes, with $150M already in Q1 (HealthLeaders, Fierce Healthcare).
  • 03Supplemental payments are becoming an operating capability, not a windfall: HCA said Q1 Medicaid program net benefit was about $200M vs $80M expected (HealthLeaders, Fierce Healthcare), putting state-by-state reimbursement strategy on the CFO’s critical path.

Sep 5, 2026

Dental practice exits are turning into multi-year projects, not last-year decisions

Dental practice exits are turning into multi-year projects, not last-year decisions

Associate-led dental practice successions can take 3–5+ years. Dental Economics says associate-to-buyout timelines often run three to five-plus years. That pushes revenue-cycle controls, buy-sell terms, and tax structure earlier, before a buyer appears.

  • 01A practical benchmark is emerging for succession: bringing in an associate with intent to buy can take a minimum of three years and often more than five, according to Dental Economics.
  • 02If accounts receivable looks “high,” it may be a bookkeeping and posting problem before it is a payer problem, a revenue-cycle diagnostic Group Dentistry Now says shows up frequently at scale.
  • 03Exit planning is now an operating system project: valuation, tax positioning, and transition support belong in the same workstream, because deal structure can lock in or foreclose tax options, per Dental Economics.

Sep 4, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512